We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · March 24, 2022

Dinaciclib: A New Potential Drug for Clear Cell Renal Cell Carcinoma

Cell Cycle (Georgetown, Tex.)

 

Additional Info

Cell Cycle (Georgetown, Tex.)
Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma
Cell Cycle 2022 Mar 04;[EPub Ahead of Print], LJ Nelson, KE Castro, B Xu, J Li, NB Dinh, JM Thompson, J Woytash, KR Kipp, OV Razorenova

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading